Fate Therapeutics
FATE
155 hedge funds and large institutions have $193M invested in Fate Therapeutics in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 30 closing their positions.
135% more call options, than puts
Call options by funds: $744K | Put options by funds: $317K
117% more capital invested
Capital invested by funds: $88.9M → $193M (+$104M)
61% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 36
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 158 → 155 (-3)
2.33% less ownership
Funds ownership: 63.74% → 61.41% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$2M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.55M |
| 4 |
Goldman Sachs
New York
|
+$1.34M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.13M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.15M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.35M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.28M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.4M |
FATE Hedge Fund Activity: Q2 2026 in Review
155 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2026, worth a combined $193M — up 117% from $88.9M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new FATE positions and 30 closed out — a net gain of 1 holder — while 58 added to existing stakes and 36 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $4.5M. The largest seller was BlackRock, cutting an estimated $5.13M.
- 155 institutional investors held Fate Therapeutics (FATE) as of Q2 2026, down from 158 in Q1 2026.
- Funds reported $193M of Fate Therapeutics stock for Q2 2026, up 117% quarter-over-quarter.
- 31 funds opened new Fate Therapeutics positions in Q2 2026 and 30 closed out, a net change of +1 holder.
- The largest Fate Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $4.5M added.
- The largest Fate Therapeutics seller in Q2 2026 was BlackRock, an estimated $5.13M sold.
Based on aggregated 13F filings for Q2 2026.